Metreleptin therapy for nonalcoholic steatohepatitis: Open-label therapy interventions in two different clinical settings

Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition. Nine male patients with relative leptin deficiency (level,

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Med (New York, N.Y. : Online) N.Y. : Online), 2021-07, Vol.2 (7), p.814-835.e6
Hauptverfasser:	Akinci, Baris, Subauste, Angela, Ajluni, Nevin, Esfandiari, Nazanene H., Meral, Rasimcan, Neidert, Adam H., Eraslan, Akin, Hench, Rita, Rus, Diana, Mckenna, Barbara, Hussain, Hero K., Chenevert, Thomas L., Tayeh, Marwan K., Rupani, Amit R., Innis, Jeffrey W., Mantzoros, Christos S., Conjeevaram, Hari S., Burant, Charles L., Oral, Elif A.
Format:	Artikel
Sprache:	eng
Schlagworte:	fatty liver disease Humans insulin resistance leptin Leptin - analogs & derivatives Leptin - therapeutic use Lipodystrophy - drug therapy Male Non-alcoholic Fatty Liver Disease - drug therapy obesity partial lipodystrophy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Recombinant leptin therapy reverses nonalcoholic steatohepatitis (NASH) in leptin-deficient lipodystrophy. We inquired if leptin therapy would improve NASH in more common forms of this heterogeneous condition. Nine male patients with relative leptin deficiency (level,
ISSN:	2666-6340 2666-6359 2666-6340
DOI:	10.1016/j.medj.2021.04.001